BRIEF-CASI Pharmaceuticals Announces Clinical Hold Of CID-103

Reuters
2024-12-26

Dec 26 (Reuters) - CASI Pharmaceuticals Inc :

* CASI PHARMACEUTICALS INC: ANNOUNCES CLINICAL HOLD OF CID-103 FOR ANTIBODY MEDIATED REJECTION $(AMR)$ OF KIDNEY TRANSPLANT

* CASI PHARMACEUTICALS: FDA PLANS TO PROVIDE FORMAL WRITTEN RESPONSE BEFORE STATUTORY DEADLINE

* CASI PHARMACEUTICALS: CID-103 IND APPLICATION SUPPORTING PHASE 1-2 STUDY OF CID-103 IN ADULTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA REMAINS OPEN

* CASI PHARMACEUTICALS: ACCRUAL TO PHASE 1-2 STUDY OF CID-103 EXPECTED TO COMMENCE IN Q1 2025

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10